State Street Corp Sells 10,785 Shares of LivaNova PLC (NASDAQ:LIVN)

State Street Corp lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 0.5% in the third quarter, Holdings Channel.com reports. The fund owned 2,039,260 shares of the company’s stock after selling 10,785 shares during the period. State Street Corp’s holdings in LivaNova were worth $107,143,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Point72 DIFC Ltd increased its position in LivaNova by 75,799.6% during the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after purchasing an additional 181,161 shares during the period. Point72 Asset Management L.P. lifted its position in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares during the period. Polar Asset Management Partners Inc. bought a new stake in shares of LivaNova during the 3rd quarter valued at about $1,949,000. Parkman Healthcare Partners LLC increased its position in shares of LivaNova by 19.5% during the third quarter. Parkman Healthcare Partners LLC now owns 101,729 shares of the company’s stock valued at $5,345,000 after buying an additional 16,570 shares during the period. Finally, NFJ Investment Group LLC raised its stake in LivaNova by 104.1% in the third quarter. NFJ Investment Group LLC now owns 96,400 shares of the company’s stock worth $5,065,000 after buying an additional 49,176 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is owned by company insiders.

LivaNova Price Performance

Shares of LivaNova stock opened at $51.50 on Monday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of 122.62 and a beta of 0.98. The stock’s 50-day simple moving average is $51.97 and its 200-day simple moving average is $51.43. LivaNova PLC has a 52 week low of $43.15 and a 52 week high of $64.47.

Analyst Ratings Changes

Several research firms have weighed in on LIVN. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Monday, November 25th. Finally, Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LivaNova has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.